PRIMARY CARE CLINICAL DIGEST JANUARY 19 2024 What’s in this issue?
1. 2. 3.
6. 7. 8. 9. •
Te Whatu Ora Immunisation Pānui January 18 2024 Proposal to enable Childhood Vaccinations through Community Pharmacy Reminder: Pharmac Consultation on a Proposal to decline Inactive Funding Applications Phenobarbitone 15 mg Tablet Brand Change to Dispensing Frequency ACC Update: Te Whatu Ora Allied Health and Scientific and Technical Pay Equity Settlement Pharmac Tender Results Building the Future of Health Virtual Hui January 30 2024 Updates for Pharmacists January 19 2024 Top Weekend Viewing (will start up again in February) To view this pānui online, please use the attached link.
•
Please see attached link to Pharmac consultation.
•
Please see attached link to Pharmac reminder consultation.
•
The funded brand of phenobarbitone 15 mg tablet is changing from PSM Phenobarbitone to Noumed Phenobarbitone from March 1 and‘stat’ dispensing is being removed from both phenobarbitone 15 mg and 30 mg tablets to align with the Misuse of Drugs Regulations 1977. API, the supplier of the ‘PSM’ brand of phenobarbitone 15 mg tablets, has closed its New Zealand manufacturing plant. Based on normal usage patterns, PSM Phenobarbitone 15 mg tablets are expected to run out in May 2024. Noumed Phenobarbitone 15 mg tablets will be listed in the Pharmaceutical Schedule from March 1 2024 and have been approved by Medsafe: Phenobarbitone Medsafe Datasheet This means people using phenobarbitone 15 mg tablets will need to change brands from PSM Phenobarbitone to Noumed Phenobarbitone between March 1 and May 2024. Clinical Advice from Pharmac’s Neurological Advisory Committee recommend people taking phenobarbitone for epilepsy need to be carefully monitored when they change brands. This advice recommended: o People using phenobarbitone for epilepsy visit their prescriber twice (one month before and one month after the change) o and have serum phenobarbital levels monitored throughout the change (two serum tests before the change and two after) Note: There are additional considerations required for people on phenobarbitone tablets who are pregnant or of child-bearing age. Please get the advice of a neurologist and refer to advice in HealthPathways. To avoid people who take phenobarbitone 15 mg tablets for epilepsy incurring any additional costs, Pharmac will fund the cost of two primary
4. 5.
Te Whatu Ora Immunisation Pānui January 18 2024 View online Proposal to enable Childhood Vaccinations through Community Pharmacy View online Reminder: Pharmac Consultation on a Proposal to decline Inactive Funding Applications View online Phenobarbitone 15 mg Tablet Brand Change to Dispensing Frequency
•
• • •
• •